Akebia Therapeutics (AKBA) Other Gross PP&E Adjustments (2016 - 2025)
Historic Other Gross PP&E Adjustments for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to -$6.4 million.
- Akebia Therapeutics' Other Gross PP&E Adjustments rose 3892.62% to -$6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.4 million, marking a year-over-year increase of 3892.62%. This contributed to the annual value of -$9.7 million for FY2024, which is 4800.8% up from last year.
- Per Akebia Therapeutics' latest filing, its Other Gross PP&E Adjustments stood at -$6.4 million for Q3 2025, which was up 3892.62% from -$7.6 million recorded in Q2 2025.
- In the past 5 years, Akebia Therapeutics' Other Gross PP&E Adjustments registered a high of -$6.4 million during Q3 2025, and its lowest value of -$32.6 million during Q1 2022.
- Its 5-year average for Other Gross PP&E Adjustments is -$19.1 million, with a median of -$18.6 million in 2023.
- Its Other Gross PP&E Adjustments has fluctuated over the past 5 years, first plummeted by 3080.8% in 2022, then skyrocketed by 5578.34% in 2023.
- Over the past 5 years, Akebia Therapeutics' Other Gross PP&E Adjustments (Quarter) stood at -$28.6 million in 2021, then rose by 19.86% to -$22.9 million in 2022, then increased by 18.93% to -$18.6 million in 2023, then skyrocketed by 48.01% to -$9.7 million in 2024, then soared by 34.13% to -$6.4 million in 2025.
- Its Other Gross PP&E Adjustments was -$6.4 million in Q3 2025, compared to -$7.6 million in Q2 2025 and -$8.1 million in Q1 2025.